Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial
- PMID: 25316904
- PMCID: PMC4234734
- DOI: 10.1503/cmaj.140764
Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial
Expression of concern in
-
Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial.CMAJ. 2018 Jul 3;190(26):E808. doi: 10.1503/cmaj.180791. CMAJ. 2018. PMID: 29970374 Free PMC article. No abstract available.
Abstract
Background: Little evidence exists on the effect of an energy-unrestricted healthy diet on metabolic syndrome. We evaluated the long-term effect of Mediterranean diets ad libitum on the incidence or reversion of metabolic syndrome.
Methods: We performed a secondary analysis of the PREDIMED trial--a multicentre, randomized trial done between October 2003 and December 2010 that involved men and women (age 55-80 yr) at high risk for cardiovascular disease. Participants were randomly assigned to 1 of 3 dietary interventions: a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with nuts or advice on following a low-fat diet (the control group). The interventions did not include increased physical activity or weight loss as a goal. We analyzed available data from 5801 participants. We determined the effect of diet on incidence and reversion of metabolic syndrome using Cox regression analysis to calculate hazard ratios (HRs) and 95% confidence intervals (CIs).
Results: Over 4.8 years of follow-up, metabolic syndrome developed in 960 (50.0%) of the 1919 participants who did not have the condition at baseline. The risk of developing metabolic syndrome did not differ between participants assigned to the control diet and those assigned to either of the Mediterranean diets (control v. olive oil HR 1.10, 95% CI 0.94-1.30, p = 0.231; control v. nuts HR 1.08, 95% CI 0.92-1.27, p = 0.3). Reversion occurred in 958 (28.2%) of the 3392 participants who had metabolic syndrome at baseline. Compared with the control group, participants on either Mediterranean diet were more likely to undergo reversion (control v. olive oil HR 1.35, 95% CI 1.15-1.58, p < 0.001; control v. nuts HR 1.28, 95% CI 1.08-1.51, p < 0.001). Participants in the group receiving olive oil supplementation showed significant decreases in both central obesity and high fasting glucose (p = 0.02); participants in the group supplemented with nuts showed a significant decrease in central obesity.
Interpretation: A Mediterranean diet supplemented with either extra virgin olive oil or nuts is not associated with the onset of metabolic syndrome, but such diets are more likely to cause reversion of the condition. An energy-unrestricted Mediterranean diet may be useful in reducing the risks of central obesity and hyperglycemia in people at high risk of cardiovascular disease.
Trial registration: ClinicalTrials.gov, no. ISRCTN35739639.
© 2014 Canadian Medical Association or its licensors.
Figures
References
-
- Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683–9. - PubMed
-
- Schmidt C, Bergström GML. The metabolic syndrome predicts cardiovascular events: results of a 13-year follow-up in initially healthy 58-year-old men. Metab Syndr Relat Disord 2012;10: 394–9. - PubMed
-
- Mozaffarian D, Kamineni A, Prineas RJ, et al. Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med 2008;168:969–78. - PubMed
-
- Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113–32. - PubMed
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical